Relmada Therapeutics (RLMD) Competitors $0.30 0.00 (-0.44%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.29 -0.01 (-1.92%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. OSTX, CELU, CVKD, GBIO, FBRX, MDCX, CASI, NRXP, ESLA, and LVTXShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include OS Therapies (OSTX), Celularity (CELU), Cadrenal Therapeutics (CVKD), Generation Bio (GBIO), Forte Biosciences (FBRX), Medicus Pharma (MDCX), CASI Pharmaceuticals (CASI), NRx Pharmaceuticals (NRXP), Estrella Immunopharma (ESLA), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. OS Therapies Celularity Cadrenal Therapeutics Generation Bio Forte Biosciences Medicus Pharma CASI Pharmaceuticals NRx Pharmaceuticals Estrella Immunopharma LAVA Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Is RLMD or OSTX more profitable? OS Therapies' return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% OS Therapies N/A N/A -569.57% Do insiders and institutionals hold more shares of RLMD or OSTX? 45.2% of Relmada Therapeutics shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 13.8% of OS Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer RLMD or OSTX? In the previous week, Relmada Therapeutics had 7 more articles in the media than OS Therapies. MarketBeat recorded 10 mentions for Relmada Therapeutics and 3 mentions for OS Therapies. Relmada Therapeutics' average media sentiment score of 0.65 beat OS Therapies' score of 0.04 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OS Therapies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community believe in RLMD or OSTX? Relmada Therapeutics received 10 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% OS TherapiesOutperform Votes7100.00% Underperform VotesNo Votes Do analysts rate RLMD or OSTX? Relmada Therapeutics presently has a consensus target price of $4.25, indicating a potential upside of 1,332.42%. OS Therapies has a consensus target price of $17.50, indicating a potential upside of 980.25%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than OS Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00OS Therapies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has preferable valuation and earnings, RLMD or OSTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.10OS TherapiesN/AN/A-$7.79MN/AN/A SummaryRelmada Therapeutics beats OS Therapies on 7 of the 13 factors compared between the two stocks. Remove Ads Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.95M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E Ratio-0.107.1723.4118.71Price / SalesN/A218.12387.6790.64Price / CashN/A65.6738.1734.64Price / Book0.106.386.894.23Net Income-$98.79M$142.12M$3.20B$247.34M7 Day Performance0.13%-5.15%-3.04%-2.27%1 Month Performance14.12%-7.55%1.53%-5.79%1 Year Performance-93.62%-11.06%9.36%-0.92% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics3.8911 of 5 stars$0.30-0.4%$4.25+1,332.4%-93.6%$8.95MN/A-0.1010Earnings ReportNews CoverageOSTXOS Therapies2.3805 of 5 stars$1.63+1.2%$17.50+973.6%N/A$35.48MN/A0.00N/ACELUCelularity0.3225 of 5 stars$1.49-3.9%N/A-66.1%$35.47M$48.20M0.00220Short Interest ↑CVKDCadrenal Therapeutics2.5761 of 5 stars$19.87+4.1%$32.00+61.0%N/A$35.43MN/A-2.984Short Interest ↑GBIOGeneration Bio4.2936 of 5 stars$0.53+10.4%$7.33+1,283.6%-89.5%$35.40M$18.58M-0.24150Short Interest ↓Positive NewsHigh Trading VolumeFBRXForte Biosciences2.9896 of 5 stars$5.52-4.8%$23.58+327.2%+29,345.6%$35.29MN/A-0.345News CoverageGap UpMDCXMedicus PharmaN/A$2.95-10.3%$10.00+239.0%N/A$35.17MN/A0.00N/AEarnings ReportGap UpCASICASI Pharmaceuticals4.3255 of 5 stars$2.26+1.8%$6.00+165.5%-40.3%$35.01M$22.06M-1.01180Analyst ForecastShort Interest ↓Positive NewsNRXPNRx Pharmaceuticals2.592 of 5 stars$2.05-12.8%$31.67+1,444.7%-95.7%$34.68MN/A-0.962ESLAEstrella Immunopharma2.4524 of 5 stars$0.96+4.0%$16.00+1,571.5%-23.5%$34.63MN/A-3.68N/APositive NewsLVTXLAVA Therapeutics2.4827 of 5 stars$1.31+0.8%$3.17+141.7%-61.3%$34.45M$7.35M-1.2760Earnings ReportShort Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies OS Therapies Alternatives Celularity Alternatives Cadrenal Therapeutics Alternatives Generation Bio Alternatives Forte Biosciences Alternatives Medicus Pharma Alternatives CASI Pharmaceuticals Alternatives NRx Pharmaceuticals Alternatives Estrella Immunopharma Alternatives LAVA Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLMD Stock Free RLMD Stock Alerts